PRAXIS PRECISION MEDICINES news, videos and press releases
For more news please use our advanced search feature.
PRAXIS PRECISION MEDICINES - More news...
PRAXIS PRECISION MEDICINES - More news...
- Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Praxis Precision Medicines to Participate in Upcoming Investor Conferences
- Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2024 Financial Results
- Praxis Precision Medicines to Report First Quarter 2024 Financial Results on Monday, May 13, 2024
- Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Praxis Precision Medicines to Present on Ulixacaltamide at the American Academy of Neurology 2024 Annual Meeting
- Praxis Precision Medicines to Participate in Upcoming April Conferences
- Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Praxis Precision Medicines, Inc. Announces Pricing of $200 Million Public Offering
- Praxis Precision Medicines, Inc. Announces Proposed Public Offering
- Praxis Precision Medicines Reports Positive Results of PRAX-628 Study Evaluating Photo Paroxysmal Response (PPR) Achieving 100% Response in Treated Patients
- Praxis Precision Medicines to Host PRAX-628 Program Update
- Praxis Precision Medicines Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Results
- Praxis Precision Medicines to Participate in TD Cowen’s 44th Annual Health Care Conference
- Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Praxis Precision Medicines, Inc. Announces Pricing of $150.0 Million Public Offering
- Praxis Precision Medicines, Inc. Announces Proposed Public Offering
- Praxis Precision Medicines Provides Update on Advancing Clinical Stage Portfolio
- Praxis Precision Medicines Announces Licensing and Collaboration Agreement with Tenacia Biotechnology for Ulixacaltamide in Greater China
- Praxis Precision Medicines to Showcase Largest Pipeline of Precision Epilepsy Programs and Breadth of Commitment to Epilepsy Treatments at Upcoming Meetings
- Praxis Precision Medicines to Present at the Piper Sandler 35th Annual Healthcare Conference
- Praxis Precision Medicines Receives PRIME Designation from the EMA for elsunersen (PRAX-222) for Treatment of SCN2A Gain of Function Developmental Epilepsies
- Praxis Precision Medicines Provides Corporate Update and Reports Third Quarter 2023 Financial Results
- Praxis Precision Medicines to Present at Truist Securities BioPharma Symposium
- Praxis Precision Medicines Provides Portfolio Update at 2023 R&D Day
- Praxis Precision Medicines To Host Hybrid R&D Day on Monday, October 2, 2023
- Praxis Precision Medicines to Present at H.C. Wainwright 25th Annual Global Investment Conference
- Praxis Precision Medicines to Present Data from Epilepsy Portfolio at the 35th International Epilepsy Congress
- Praxis Precision Medicines to Present Analyses of Patient-Focused, Clinically Meaningful Endpoints from Essential1 Study of Ulixacaltamide in Essential Tremor at the 2023 MDS International Congress
- Praxis Precision Medicines Provides Corporate Update and Reports Second Quarter 2023 Financial Results
